FY2024 EPS Estimates for Vanda Pharmaceuticals Inc. Lowered by Cantor Fitzgerald (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Stock analysts at Cantor Fitzgerald reduced their FY2024 earnings per share estimates for Vanda Pharmaceuticals in a report issued on Wednesday, July 24th. Cantor Fitzgerald analyst C. Duncan now expects that the biopharmaceutical company will earn ($0.61) per share for the year, down from their previous estimate of ($0.23). Cantor Fitzgerald has a “Overweight” rating and a $11.00 price objective on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($0.23) per share.

Separately, StockNews.com started coverage on shares of Vanda Pharmaceuticals in a research note on Saturday, July 20th. They set a “hold” rating on the stock.

Vanda Pharmaceuticals Stock Down 0.3 %

Shares of NASDAQ:VNDA opened at $6.15 on Friday. The firm has a market capitalization of $357.93 million, a PE ratio of -76.88 and a beta of 0.75. The company has a 50-day moving average price of $5.70 and a two-hundred day moving average price of $4.77. Vanda Pharmaceuticals has a twelve month low of $3.30 and a twelve month high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.12). Vanda Pharmaceuticals had a negative return on equity of 0.90% and a negative net margin of 2.75%. The firm had revenue of $47.46 million during the quarter, compared to analysts’ expectations of $48.50 million.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in VNDA. GSA Capital Partners LLP boosted its position in shares of Vanda Pharmaceuticals by 39.8% in the fourth quarter. GSA Capital Partners LLP now owns 567,756 shares of the biopharmaceutical company’s stock valued at $2,396,000 after acquiring an additional 161,737 shares during the period. Susquehanna Fundamental Investments LLC bought a new position in shares of Vanda Pharmaceuticals in the first quarter worth $1,158,000. Acadian Asset Management LLC raised its position in shares of Vanda Pharmaceuticals by 4.7% in the first quarter. Acadian Asset Management LLC now owns 2,370,335 shares of the biopharmaceutical company’s stock worth $9,740,000 after buying an additional 107,203 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Vanda Pharmaceuticals by 352.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,658 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 5,186 shares during the period. Finally, Public Employees Retirement System of Ohio grew its position in Vanda Pharmaceuticals by 13.7% during the third quarter. Public Employees Retirement System of Ohio now owns 75,648 shares of the biopharmaceutical company’s stock worth $327,000 after buying an additional 9,100 shares in the last quarter. Institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.